ICMR, Serum Institute complete enrollment of phase 3 clinical trials of COVID-19 vaccine COVISHIELD

Phase 3 of the COVISHIELD human trials will involve 1600 participants.

tech2 News Staff November 12, 2020 13:52:52 IST
ICMR, Serum Institute complete enrollment of phase 3 clinical trials of COVID-19 vaccine COVISHIELD

India can provide quality, low-cost vaccines not only for internal use but for global purposes.

Serum Institute of India (SII) and the Indian Council of Medical Research (ICMR) have announced that the enrolment process of phase 3 of its clinical trials for COVISHIELD has been completed as of 31 October. Covishield is being developed at the Serum Institute laboratory in Pune with a master seed from Oxford University/Astra Zeneca trial. It is also being tested in trials in the UK, Brazil, South Africa and the USA. SII partnering with ICMR are conducting Phase 2/3 clinical trial of COVISHIELD at 15 different centres, across the country.

Phase 3 of the COVISHIELD human trials will involve 1600 participants.

ICMR is the apex body for biomedical research in India and is funding the clinical trial site fees. Meanwhile, SII is funding all the other expenses for the trials.

SII has also manufactured 40 million doses of the vaccines, under the at-risk manufacturing and stockpiling license from DCGI.

"The promising results of the trials so far give confidence that Covishield could be a realistic solution to the deadly pandemic," Serum Institute said in a press release.

ICMR and SII have also collaborated to get the US-based Novavax's COVID-19 vaccine candidate to India. Called COVOVAX, the vaccine is currently being tested in South Africa and in the UK. Trials will soon begin in the US as well.

SII will be testing the vaccine in a Phase 3 trial in India as well. However, no exact date has been given.

Dr Balram Bhargava, Director General of ICMR said in a statement, “At present, India plays a prominent role in vaccine development and manufacturing globally. Buoyed by the latest technology and well-equipped facilities, SII has continually proven its research and manufacturing prowess."

He added, "The partnership is our contribution to lending our expertise and support to bolster our fight against the global pandemic.”

Updated Date:

also read

States asked to hold vaccination camps for booster dose at stations, religious sites
Health

States asked to hold vaccination camps for booster dose at stations, religious sites

The precaution dose coverage among the 64,89,99,721 eligible population was eight per cent till 14 July

Centre to soon approve Biological E's Corbevax as precaution dose for people above 18 years
Health

Centre to soon approve Biological E's Corbevax as precaution dose for people above 18 years

If approved by the government, this would be the first time a booster dose of a COVID vaccine different from the one used for primary vaccination would be allowed in the country

COVID-19: Corbevax approved as precaution dose for adults vaccinated with Covaxin, Covishield
India

COVID-19: Corbevax approved as precaution dose for adults vaccinated with Covaxin, Covishield

This is for the first time that a booster dose that is different from the one used for primary vaccination against Covid has been allowed in the country